Who can use Endobloc(Ambrisentan)?

Endobloc (Ambrisentan) is indicated for adult patients with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity and delay clinical worsening, including use in combination with tadalafil.

Indicated Patient Population

Endobloc is approved for adults with PAH (WHO Group 1), including idiopathic, heritable, or connective tissue disease-associated etiologies. It is used as monotherapy or combined with tadalafil to reduce disease progression and hospitalization risks. Efficacy was established in patients predominantly in WHO Functional Class II–III.